Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Significance: Synthetic nanoparticles containing either protein or peptide antigen and the immunosuppressant rapamycin are capable of inducing durable and specific resistance to mounting immune responses toward the antigen. This immunological tolerance operates on lymphocytes even after multiple immunogenic challenges with the antigen and adding enhancers of immune responses (adjuvants). As a result, the animals treated with these tolerogenic nanoparticles (tNPs) show reduced allergic hypersensitivity disorders, protection from disease relapse in a model of multiple sclerosis, and prevention of inhibitory antidrug antibody responses in an animal model of hemophilia A. These results show the potential for nanocarriers to modify the immunoreactivity of a given molecule by providing tolerogenic instructions to the immune system, thereby preventing or reversing pathological and neutralizing immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, tolerogenic rapamycin nanoparticles, but not rapamycin in free form, have been shown to be able to inhibit both cellular and humoral immune response and induce Tregs in mice (40).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [40]
Citations
Cites
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106 · cited 7×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“In fact, free rapamycin, administered at an equivalent dose as that used in tNP treatment, showed the opposite trend with respect to inhibition of OVA-specific T-cell expansion and induction of antigen-specific Tregs, perhaps due to the direct effect of free rapamycin on enhancing effector memory T-cell formation (40).”
Goodnow, C. C., Crosbie, J., Adelstein, S., Lavoie, T. B., Smith-Gill, S. J., Brink, R. A., Pritchard-Briscoe, H., Wotherspoon, J. S., Loblay, R. H., Raphael, K., et al. (1988) · Nature · doi:10.1038/334676a0 · Cited by 1,565 · cited 1×
“The transgenic BCR is specific for hen egg lysozyme (HEL), and the presence of this protein results in cell activation of MD4 B cells in vivo and in vitro (33).”
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 2×
“However, conventional therapy with free rapamycin requires chronic systemic administration, resulting in broad immunosuppression due to its direct effect on lymphocytes (28), whereas low doses of rapamycin may paradoxically augment effector T-cell memory (29).”
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594 · cited 8×
“Thomson and colleagues (26, 27) demonstrated that treating DCs with rapamycin, an inhibitor of the mTOR pathway, induces a tolerogenic DC phenotype capable of inducing Treg differentiation and antigen-specific immune tolerance that is resistant to the proinflammatory cascade triggered by TLR signaling.”
InfluentialTargeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593 · cited 1×
“tNPs containing both antigen and rapamycin were prepared using a water-in-oil-in-water double emulsion solvent evaporation method (44, 45).”
How Tolerogenic Dendritic Cells Induce Regulatory T Cells
Maldonado, R. A., & von Andrian, U. H. (2010) · Advances in Immunology · doi:10.1016/b978-0-12-380995-7.00004-5 · Cited by 541 · cited 1×
“The codelivery of antigen and rapamycin provide an instruction set that could allow for the conditioning of tolerogenic DCs capable of inducing CD4+ Treg (22, 23).”
Self-citationUpdated assessment of the prevalence, spectrum and case definition of autoimmune disease
Hayter, S. M., & Cook, M. C. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.02.001 · Cited by 464 · cited 1×
“Clin Rev Allergy Immunol 37(2):114–124.”
Cited by
Items 401–452 of 452
Nachod, B. E., Thatte, A. S., Palanki, R., & Mitchell, M. J. (2025) · Angewandte Chemie · doi:10.1002/ange.202524097 · Cited by 1
Molecular origin, discovery, validation and application of neoantigens
Lyu, Q., & Hu, S. (2026) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2026.101143 · Cited by 4
“This localized action minimizes systemic exposure to encapsulated tolerogenic agents like rapamycin, vitamin D3 or TGF-β [ 306 ].”
External temperature control of lymphatic drainage of thermo-sensitive nanomaterials
Zhang, M., Chen, W., Hong, Y., Chen, H., & Wang, C. (2018) · Biomaterials Science · doi:10.1039/c8bm01298a · Cited by 1
Immunogenicity Risks for Naturally Derived Complex Drugs
Rao, R., & Verthelyi, D. I. (2019) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-11751-1_13 · Cited by 1
Macrophage Targeting by Nanocarriers for Therapy of Autoimmune Diseases
Biswas, L., Yadav, M., Singh, P., Talegaonkar, S., & Verma, A. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_14 · Cited by 1
Peine, K. J., Chen, N., Bachelder, E. M., & Ainslie, K. M. (2018) · IGI Global eBooks · doi:10.4018/978-1-5225-7122-3.ch007 · Cited by 1
Alex, T. S., Lang, D. K., Zakir, F., Mirza, A., & Iqbal, Z. (2022) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-031-14848-4_1 · Cited by 1
Applications of Micro/Nanorobot Swarms in Biomedicine
Zhang, L., Yang, S., Wang, Q., & Jin, D. (2023) · Springer tracts in electrical and electronics engineering · doi:10.1007/978-981-99-3036-4_10 · Cited by 1
A new era of nanotechnology applied in neurological disease treatments
Pandit, J., Bharti, C., Gupta, S., Munawar, S. M., Sabjan, K. B., Quadri, K., Waziri, A., Salawi, A., & Alam, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00031-2 · Cited by 1
Peine, K. J., Chen, N., Bachelder, E. M., & Ainslie, K. M. (2016) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-0754-3.ch002
Kuo, R. (2017) · Deep Blue (University of Michigan)
Nanoparticulate Immunotherapy: An Intelligent Way to Tailor Make Our Defense System
Acharya, R., Saha, S., Ray, S., & Chakraborty, J. (2017) · Springer eBooks · doi:10.1007/978-981-10-3647-7_13
Generation of a novel mouse model for the study of autoimmune liver disease overlap syndrome
Fuchs, S., Bayer, M., Manns, M. P., Hintermann, E., & Christen, U. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)31147-4
Patent Highlights February–March 2017
Mucke, H. A. (2017) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2017-0016
Synthesis of peptide conjugates with vitamins for induction of antigen‐specific immunotolerance
Yuzuriha, K., Yoshida, A., Li, S., Kishimura, A., Mori, T., & Katayama, Y. (2020) · Journal of Peptide Science · doi:10.1002/psc.3275 · Cited by 3
Self-Delivery Drug Amphiphilies In Chemotherapy And Immunotherapy
Xi, J. (2019) · Human Biology
Ishizuka, A. S., Lynn, G. M., & Jewell, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821440-4.00002-5
Programming supramolecular peptide materials for immunological applications
Lau, C. Y. J. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/604
PE066 児童の作文指導についての授業実践 : ベテラン教師の授業分析より
千亜紀, 石., 山田, 剛., & 喜久子, 三. (2009) · 日本教育心理学会総会発表論文集 · doi:10.20587/pamjaep.51.0_480
Fehlings, M. G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734958350.793573257
Applications of nanotechnology in allergy and asthma
Pervaiz, S., Cheema, S. M., Shaheen, T., Tahir, R., Haider, Z., & Shamim, S. (2023) · Journal of Basic & Clinical Medical Sciences · doi:10.58398/0002.000008
Role of regulatory T cells in pathogenesis and therapeutics of multiple sclerosis
Szpakowski, P., Ksiazek-Winiarek, D. J., & Glabinski, A. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13947-5.00041-5
Wraith, D. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98808-7.00019-9
Guillet, E. (2022) · theses.fr (ABES) · doi:10.70675/ff322d9az924cz4a55zb97aza18c677cb6af
Applying Fc-fusion proteins to tolerize perinatally and block inhibitor formation
Scott, D. W. (2025) · Haematologica · doi:10.3324/haematol.2025.287742
Self-citationVillela-Nava, A. L., Song, S., Xie, J., Ahlquist, C. S. E., Siahaan, T. J., & Kim, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01132
Carroll, K. R. (2018) · OhioLink ETD Center (Ohio Library and Information Network)
Harnessing Nanotechnology in Modulating Neuroimmune Axis
Tiwari, A., Maharana, K. C., Dutta, B. J., & Singh, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5088-3_2
Yang, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s588680
“67 This form of treatment, also known as allergen-specific immunotherapy (AIT), has yielded encouraging results in treating inflammatory conditions such as allergies and autoimmune diseases, representing a potential curative approach for asthma.”
Material designs for maintenance of immunological homeostasis
Yuzuriha, K. (2020) · Institutional Repositories DataBase (IRDB)
Torelogenic nanoparticles for beta cell antigen delivery in type-1 diabetes
Dubreil, C. (2018) · theses.fr (ABES) · doi:10.70675/a1e93e75ze22az4758z9493z0fab68188130
Li, D. U., Fang-Fang, L. I. U., & Wang, W.-Y. (2026) · Shengming kexue · doi:10.3724/cbls.2026081
Engineering nanoplatforms for autoimmune treatment: From synthetic strategies to bioinspired designs
Wang, Y., Ninsuvannakul, C., Zhang, G., Robinson, S., & Hasani‐Sadrabadi, M. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115083
Wouters, A., Mathieu, C., & Gysemans, C. A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104120 · Cited by 1
Vicidomini, A., Boisgérault, F., Romano, G., Guarnaccia, C., Vidal, P., Collaud, F., Soria, L. R., Sabbata, G. D., Tedesco, N., Lisjak, M., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201793
“25,50 ImmTOR has shown efficacy in other models, 20–23,29 Several key observations emerged from the present study.”
Self-citationBiomaterial‐Focused Strategies Targeting Dendritic Cells for Autoimmune Disease Treatment
Kumar, A. V. S., & Babensee, J. E. (2026) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.70107
Ahmed, A. K. K., & almutairi, K. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6980718
Nanoparticle-Enabled Modulation of the Bone Immune Microenvironment for Enhanced Regeneration
Varol, G. D., Çiftçi, F., Özarslan, A. C., Erarslan, A., & Kızılkurtlu, A. A. (2026) · Bioengineering · doi:10.3390/bioengineering13070755
Unleashing the prospects of nanomaterials in the treatment of autoimmune and inflammatory diseases
Gayathri, V. G., Rasheed, P. A., & Bayry, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119706
Liu, Y., Zheng, W., Cong, S., Xu, F., Zhang, Y., & Wang, D. Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s625156
mRNA therapeutics for restoring immune tolerance in autoimmune diseases
Zouali, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104776
Jia, S., Weiser, Z., Rajasekaran, M., DiMitri, L. G., & Deak, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1897468
Mikuls, T. R., Neogi, T., & Gaffo, A. (2026) · BioDrugs · doi:10.1007/s40259-026-00808-7
Yu, K., Xu, X., Gao, J., 邢洁, Yin, X., Song, Q., Wen, K., Lin, X., Cai, X., & Zhong, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1955727
de Carvalho, J. F., Caldas, C. A. M., & Shoenfeld, Y. (2026) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.111225.rba
“29 Across diseases, tolerogenic vaccines appear most promising when applied early in the autoimmune process, before extensive epitope spreading and irreversible tissue damage occur.”
Tong, A. P. S., Poljakov, K., Lane, D. D., Laidlaw, G., Monsky, W. L., McGregor, H., Yeung, R. S., Grassberger, C., Altreuter, D. H., Hall, E. T., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015165
“Maldonado et al 75 demonstrated that only rapamycin encapsulated within PLGA nanoparticles, not free rapamycin, could induce antigen-specific tolerance, illustrating how nanoparticle formulation governs local immune engagement.”
InfluentialSelf-citation
Metadata
- Authors
- Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., Johnston, L., Farokhzad, O. C., Langer, R., Scott, D. W., von Andrian, U. H., & Kishimoto, T. K.
- Affiliations
- Selecta Biosciences (United States) (US)
- Uniformed Services University of the Health Sciences (US)
- Brigham and Women's Hospital (US)
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;
- Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115-6017; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2014-12-29
- Volume
- 112
- Issue
- 2
- Pages
- E156-65
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4299193
- OpenAlex
- W2092747941
- Cited by
- 441
- References
- 48
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 31 · 2023: 36 · 2022: 45 · 2021: 42 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 50 · 2016: 24 · 2015: 23
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Juvenile Diabetes Research Foundation International (15-2011-265)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- polymeric nanoparticles, rapamycin, biodegradable nanoparticles, TLR agonists, regulatory T cells, B cell tolerance, T cell activation inhibition, experimental autoimmune encephalomyelitis, hemophilia A, factor VIII, hypersensitivity, autoimmune disease, allergy, antidrug antibodies, immunomodulation
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Antigens, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Factor VIII, Female, Hemocyanins, Hemophilia A, Humans, Hypersensitivity, Delayed, Immune Tolerance, Immunosuppression Therapy, Immunosuppressive Agents, Mice, Inbred BALB C, Oligodeoxyribonucleotides, Ovalbumin, Peptide Fragments, Peptides, Polyglycolic Acid, Proteins, Recombinant Proteins, CD4-Positive T-Lymphocytes, Lactic Acid, Sirolimus, Mice, Nanoparticles, Nanocapsules, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.